MX357841B - Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen. - Google Patents

Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen.

Info

Publication number
MX357841B
MX357841B MX2014010345A MX2014010345A MX357841B MX 357841 B MX357841 B MX 357841B MX 2014010345 A MX2014010345 A MX 2014010345A MX 2014010345 A MX2014010345 A MX 2014010345A MX 357841 B MX357841 B MX 357841B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
receptor antagonists
same
hormone receptor
releasing hormone
Prior art date
Application number
MX2014010345A
Other languages
English (en)
Other versions
MX2014010345A (es
Inventor
Kim Jae-Sun
Lee Bong-Yong
Ah Shin Young
Park Euisun
Kim Seon-Mi
Lee Minhee
Lee So-Young
A Lee Jung
Han Min-Young
Ahn Jaeseung
Yoo Taekyung
Kim Hun-Taek
Original Assignee
Tiumbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiumbio Co Ltd filed Critical Tiumbio Co Ltd
Publication of MX2014010345A publication Critical patent/MX2014010345A/es
Publication of MX357841B publication Critical patent/MX357841B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona antagonistas de los receptores de la hormona liberadora de gonadotropina y la composición farmacéutica que los contiene, la cual es útil para la prevención o tratamiento de una enfermedad relacionada con la hormona sexual, como puede ser endometriosis, amenorrea, menstruación irregular, mioma uterino, fibroides uterinos, enfermedad de ovario poliquístico, lupus eritematoso, hipertricosis, pubertad precoz, estatura corta, acné, alopecia, neoplasmas dependientes del esteroide gonadal, adenoma hipofisario productor de gonadotropina, apnea del sueño, síndrome de intestino irritado, síndrome premenstrual, hiperplasia prostática benigna, contracepción e infertilidad, así como enfermedad de Alzheimer.
MX2014010345A 2012-02-28 2013-02-28 Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen. MX357841B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120020479 2012-02-28
PCT/KR2013/001660 WO2013129879A1 (en) 2012-02-28 2013-02-28 Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
MX2014010345A MX2014010345A (es) 2014-11-14
MX357841B true MX357841B (es) 2018-07-26

Family

ID=49082998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010345A MX357841B (es) 2012-02-28 2013-02-28 Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen.

Country Status (11)

Country Link
US (1) US9481684B2 (es)
EP (1) EP2820021B1 (es)
JP (1) JP6209171B2 (es)
KR (1) KR101495260B1 (es)
CN (2) CN105732649B (es)
AU (1) AU2013226661B2 (es)
BR (1) BR112014021331B1 (es)
CA (1) CA2865547C (es)
ES (1) ES2613856T3 (es)
MX (1) MX357841B (es)
WO (1) WO2013129879A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005142A (es) * 2013-10-30 2016-10-28 Shanghai hengrui pharmaceutical co ltd Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CN109983017B (zh) * 2017-07-28 2021-11-12 江苏恒瑞医药股份有限公司 一种嘧啶酮并杂芳基类衍生物的制备方法及其中间体
KR101973074B1 (ko) 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
CN109651265A (zh) * 2019-02-16 2019-04-19 安徽诺全药业有限公司 一种Elagolix的制备方法
WO2020196946A1 (ko) 2019-03-26 2020-10-01 노벨파마 주식회사 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种促性腺激素释放激素受体拮抗剂中间体的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163325A1 (en) * 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
US6156772A (en) * 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
KR20020045609A (ko) * 1999-10-15 2002-06-19 추후기재 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법
JP2005500356A (ja) * 2001-08-02 2005-01-06 ニューロクライン バイオサイエンシーズ， インコーポレイテッド ゴナドトロピン放出ホルモンレセプターアンタゴニスト
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
MXPA04012566A (es) * 2002-06-13 2005-04-19 Pfizer Agentes no peptidicos reguladores de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
JPWO2007011072A1 (ja) * 2005-07-22 2009-02-05 武田薬品工業株式会社 早発排卵の防止剤
ES2549502T3 (es) * 2009-11-20 2015-10-28 Sk Chemicals Co., Ltd. Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen

Also Published As

Publication number Publication date
MX2014010345A (es) 2014-11-14
ES2613856T3 (es) 2017-05-26
EP2820021A4 (en) 2015-10-21
BR112014021331A2 (es) 2017-06-20
CN105732649B (zh) 2019-02-05
JP2015510868A (ja) 2015-04-13
CN105732649A (zh) 2016-07-06
EP2820021B1 (en) 2016-11-30
KR20130102002A (ko) 2013-09-16
CN104136441B (zh) 2016-09-28
AU2013226661B2 (en) 2017-08-31
BR112014021331B1 (pt) 2020-12-15
JP6209171B2 (ja) 2017-10-04
CN104136441A (zh) 2014-11-05
CA2865547C (en) 2020-03-10
EP2820021A1 (en) 2015-01-07
WO2013129879A1 (en) 2013-09-06
KR101495260B1 (ko) 2015-02-26
US20150166558A1 (en) 2015-06-18
CA2865547A1 (en) 2013-09-06
AU2013226661A1 (en) 2014-10-16
BR112014021331A8 (pt) 2017-10-10
US9481684B2 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
MX357841B (es) Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen.
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
WO2006058012A3 (en) Gonadotropin releasing hormone receptor antagonists
JOP20090061B1 (ar) طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
SG11202001439QA (en) Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis
WO2011098436A3 (de) Progesteronrezeptorantagonisten
PH12020500400A1 (en) Il-33 antagonist-containing therapeutic agent for endometriosis
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
PH12015502318A1 (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
FR2962850B1 (fr) Dispositif et procede pour former sur un nanofil en semi-conducteur un alliage de ce semi-conducteur avec un metal ou un metalloide.
Jinling Sidelights of CAFIU Delegation's Visit to Japan and Thailand
Lee et al. Evaluation of Alkali Recovery Agents
TH142786A (th) ของผสมบิทูเมนที่ดำเนินกรรมวิธีสำหรับเทถนนที่อุณหภูมิลดลง
Oh et al. Analysis of spin-orbit coupling effects in the Pt-Si nanowires on Si (110) surface
Kim et al. The New Aluminum Development for Condenser Tube
Lee et al. Influence of van der Waals corrected xc-functionals on the anisotropic mechanical properties of coinage metals
Jo et al. The Evaluation of Technology for Temperature Reduction of Mixing & Compaction for Polymer Modified Asphalt
Zhang et al. Retraction of “Phase Equilibrium for the Ternary System NaH2PO4+ KH2PO4+ H2O at 288.15 and 318.15 K”
Hui et al. China expands shape protection
Kumar et al. Inhomogeneous Growth of PtSi Studied by Spatially Resolved Photoelectron Spectroscopy
Sim et al. A Study On the technique of Tank use ratio Prediction in Petrochemistry process
Song et al. Submicron aerosol characterization during CARES 2010 field campaign using a high resolution aerosol mass spectrometry at the suburban site
Kim et al. Fundamental Study on Improvement of Fire-Resistance and Field Application of Refractory Mortar of Tunnel Structures
Hong et al. Analysis of Arc-Flash Hazards and Mitigation
Li et al. Probing voltage induced bond rupture in a molecular junction

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TIUMBIO CO., LTD.

FG Grant or registration